A Phase 4 interventional study of pioglitazone and rosiglitazone in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Terminated at 331 sites in 25 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-04-18.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 7 that started in 2009, is one of 57 in phase 4, and was the 60th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 20+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–80
By country, each count listing its studies:
Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 11 · Phase 3 33 · Phase 4 57
First in 2000; this study’s year is marked. 7 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,332 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 103 across the 122 interventional studies. Of the 96 that completed or were terminated, 31 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 122 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 133 finished, 46 (35%) have results posted.
Among the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline, this one is the 4th largest by enrollment of the 125 interventional ones that give a count, is one of 22 that started in 2009, is one of 23 in phase 4, and was the 71st registered.
GlaxoSmithKline’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
4 of the studies testing pioglitazone in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT05305287The University of Texas Health Science Center at San AntonioQuantifying Hepatic Mitochondrial Fluxes in Humans | 2027-03-31 |
| NCT04501406University of FloridaLow-Dose Pioglitazone in Patients With NASH (AIM 2) | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 136 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will answer two separate questions.
The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard of care without rosiglitazone or pioglitazone in patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease.
The second question will compare the effects of long-term supplementation of vitamin D on death and cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age ≥ 50 years and evidence of vascular disease defined as ≥1of:
Age ≥ 55 years and evidence of subclinical vascular disease defined as ≥1 of:
history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram
Age ≥ 60 years and at least 2 of the following cardiovascular disease risk factors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PIO tablet was administered in the dose of 30 milligrams (mg) OD initially and could be titrated to a maximum dose of 45 mg at or after the 6-month visit. After 1 year of treatment, the dose of PIO was increased to 45 mg OD for the duration of 5.5 years.
Drug: pioglitazone
RSG tablet was administered in the dose of 4 mg OD initially and could be titrated to a maximum dose of 8 mg at or after the 6-month visit. After 1 year of treatment, the dose of RSG was increased to 8 mg OD for the duration of 5.5 years.
Drug: rosiglitazone
Matching placebo tablet was administered once a day (OD) for the duration of 5.5 years
Drug: placebo
Active comparator
Dietary Supplement: Vitamin D
Placebo Comparator
Dietary Supplement: Placebo
Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
Vitamin D factor intervention
Vitamin D factor intervention
Number of Participants With the Indicated Components of the Composite Cardiovascular Outcome for Thiazolidinedione (TZD)
An event adjudication committee (EAC) adjudicated all occurrences of the components of the composite cardiovascular (CV; related to heart) outcome for TZD. Components are the first occurrence of cardiovascular death for which a non-heart-related cause has not been identified; non-fatal myocardial infarction (MI) (death of heart muscle from sudden blockage of a coronary artery by blood clot not leading to death); and non-fatal stroke (rapidly developing loss of brain function\[s\] due to disturbance in the blood supply to the brain not leading to death).
Time frame: From Randomization at Visit 3 up to the Final Visit (average of 162 days)
Number of Participants With the Indicated Components of the Composite Outcome for Vitamin D
An EAC adjudicated all occurrences of the components of the composite outcome for vitamin D. Components are the first occurrence of death or cancer requiring hospitalization, treatment with medicines (chemotherapy), or surgery.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With Any Revascularization
Revascularization is defined as any surgical procedure for the provision of a new, additional, or augmented blood supply to heart muscle. Data regarding the need for any revascularization were adjudicated by the EAC and sent to the data monitoring committee (IDMC) on a regular basis for unblinded review.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With Need for Hospitalization for Any Reason
Data regarding the need for hospitalization for any reason were collected and were then forwarded to the independent data monitoring committee (IDMC) on a regular basis for unblinded review.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With Need for Hospitalization for Congestive Heart Failure (CHF), Shortness of Breath, Pneumonia, or Angina
CHF is a condition in which the heart is not able to pump adequate blood to meet the body's needs. Shortness of breath is defined as difficulty in breathing. Pneumonia is an infection of the lungs, caused by various microorganisms. Angina is defined as severe chest pain due to lack of adequate blood supply of the heart muscle because of obstruction/spasm of the heart's blood vessels. Data regarding the need for hospitalization due to any of these reasons were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With Composite Microvascular Outcome
The components of the composite microvascular outcome are retinopathy, decline in eGFR, vitrectomy, and renal replacement surgery. Retinopathy is defined as damage to the inner lining of the eye (retina). Decline in eGFR is defined as a \>=30% reduction in kidney function. Vitrectomy is a surgery to remove some or all of the fluid (vitreous humor) from the eye. Renal replacement therapy includes all the life-supporting treatments for renal failure. Data regarding the number of participants with changes in micro blood vessels (composite microvascular outcome) were collected at each visit.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With Retinopathy Requiring Laser Therapy, a Decline in Estimated Glomerular Filtration Rate (eGFR), Vitrectomy, and Renal Replacement Therapy
Retinopathy is defined as damage to the inner lining of the eye (retina). Decline in eGFR is defined as a \>=30% reduction in kidney function. Vitrectomy is a surgery to remove some or all of the fluid (vitreous humor) from the eye. Renal replacement therapy includes all the life-supporting treatments for renal failure. Data on the number of participants with all of these microvascular outcomes were collected at each visit. Data regarding the number of participants with these microvascular outcomes were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With Severe Lower Than Normal Blood Glucose Level (Hypoglycemia)
Severe hypoglycemia is defined as hypoglycemia requiring assistance from another person with either a documented plasma glucose \<=36 mg/deciliter (2.0 millimole per liter \[mmol/L\]) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration. Hypoglycemia data were obtained from outcomes reported by the site. Data regarding hypoglycemia were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With Clinical Proteinuria
Clinical proteinuria is defined as a laboratory detection of urinary protein excretion \> 0.5 grams (g) per 24 hours; spot urine analysis for albumin:creatinine ratio \>=300 milligrams/g; timed urine collection for albumin excretion \>=200 µg/minute or \>=300 mg/24 hours. Clinical proteinuria data were obtained from outcomes reported by the site.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With a Fracture
Fracture is defined as a medical condition in which there is a break in the continuity of the bone. Fractures are defined as those breaks that are self reported plus confirmed by an X-ray. Data regarding all occurrences of any fracture were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With Hepatic Enzyme Increased or Abnormal Liver Function Tests
Liver function tests are groups of clinical biochemistry laboratory blood assays designed to give information about the health of the liver. "Liver function test abnormal" and "hepatic enzyme increased" were obtained from adverse event data as reported by investigators based on the reference range of the reporting local laboratory methodology. The vitamin D arm was not analyzed for this outcome measure.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With Cognitive (Mental Processes) Decline (CD) From Baseline to the Year 2 Visit and the Final Visit
CD is equivalent to a difference of \>=1.5 units on the Digit Symbol Substitution Test (DSST) score. The DSST is a neuropsychological test sensitive to brain damage, a serious loss of cognitive ability, age, and depression. It consists of digit-symbol pairs, followed by a list of digits. Under each digit the participant was asked to write the corresponding symbol as quickly as possible. The number of correct symbols within the allowed time (90 or 120 seconds) was measured in units (one correct score equals one unit).
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Number of Participants With Erectile Dysfunction
Erectile dysfunction (ED) is sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual performance. ED was assessed by using the International Index of Erectile Dysfunction (IIED) questionnaire. This standardized and validated 15-item self-evaluation scale provides pre- and post-treatment clinic evaluations of erectile and orgasmic function, sexual desire, satisfaction with sexual intercourse, and general satisfaction.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Mean Score on Euro-QoL (EQ)-5D
Quality of life (QoL) was assessed by using the Euro-QoL (EQ)-5D, a short questionnaire used for measuring health-related QoL. The preference weights are elicited by asking participants to place hypothetical health states on a visual analogue scale from "0" to "1", whereby a score of "1" represents the best health state imaginable and "0" represents a health state equivalent to being dead. Negative states are those worse than being dead.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
Mean Score on Montreal Cognitive Assessment (MoCA) Test, as an Assessment of Cognitive Function (CF)
CF was assessed with the 30-point (pt) MoCA test, involving a short-term memory recall task (T) (5 pts), a clock-drawing T (3 pts), a 3-dimensional cube copy (1 pt), a trail-making B T (1 pt), a phonemic fluency T (1 pt), a 2-item verbal abstraction T (2 pts), an attention T (1 pt), a serial subtraction T (3 pts), digits forward/ backward (1 pt each), a 3-item confrontation naming T (3 pts), repetition of 2 syntactically complex sentences (2 pts), and orientation to time/ place (6 pts). A score of 26 or above is normal.
Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)
1332 participants were included in the TZD randomization, and 1221 of 1332 participants were included in the Vitamin D randomization.
| Milestone | Placebo | Pioglitazone (PIO) | Rosiglitazone (RSG) | Vitamin D Placebo | Vitamin D |
|---|---|---|---|---|---|
| Started | 541 | 392 | 399 | 0 | 0 |
| Completed | 533 | 388 | 393 | 0 | 0 |
| Not completed | 8 | 4 | 6 | 0 | 0 |
| Withdrew: Refused to attend final visit | 3 | 3 | 4 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Final or study hold visits not completed | 2 | 0 | 1 | 0 | 0 |
| Milestone | Placebo | Pioglitazone (PIO) | Rosiglitazone (RSG) | Vitamin D Placebo | Vitamin D |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 614 | 607 |
| Completed | 0 | 0 | 0 | 610 | 600 |
| Not completed | 0 | 0 | 0 | 4 | 7 |
| Withdrew: Refused to attend final visit | 0 | 0 | 0 | 2 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 2 | 0 |
An event adjudication committee (EAC) adjudicated all occurrences of the components of the composite cardiovascular (CV; related to heart) outcome for TZD. Components are the first occurrence of cardiovascular death for which a non-heart-related cause has not been identified; non-fatal myocardial infarction (MI) (death of heart muscle from sudden blockage of a coronary artery by blood clot not leading to death); and non-fatal stroke (rapidly developing loss of brain function\[s\] due to disturbance in the blood supply to the brain not leading to death).
| participants | Placebo | Pioglitazone (PIO) | Rosiglitazone (RSG) | Vitamin D Placebo | Vitamin D |
|---|---|---|---|---|---|
| CV Death/Non-Fatal MI/Non-Fatal Stroke | 5 | 2 | 1 | 3 | 2 |
| CV Death | 1 | 0 | 0 | 1 | 0 |
| Non-Fatal MI | 2 | 0 | 1 | 1 | 1 |
| Non-Fatal Stroke | 2 | 2 | 0 | 1 | 1 |
An EAC adjudicated all occurrences of the components of the composite outcome for vitamin D. Components are the first occurrence of death or cancer requiring hospitalization, treatment with medicines (chemotherapy), or surgery.
| participants | Placebo | Pioglitzaone | Rosiglitazone | Vitamin D Placebo | Vitamin D |
|---|---|---|---|---|---|
| Death or serious cancer | 6 | 3 | 1 | 3 | 2 |
| All death | 4 | 1 | 1 | 2 | 0 |
| Serious cancer | 2 | 2 | 0 | 1 | 2 |
Revascularization is defined as any surgical procedure for the provision of a new, additional, or augmented blood supply to heart muscle. Data regarding the need for any revascularization were adjudicated by the EAC and sent to the data monitoring committee (IDMC) on a regular basis for unblinded review.
| participants | Placebo | Pioglitazone | Rosiglitazone | VITAMIN D PLACEBO | VITAMIN D |
|---|---|---|---|---|---|
| Number of Participants With Any Revascularization | 6 | 3 | 5 | 7 | 5 |
Data regarding the need for hospitalization for any reason were collected and were then forwarded to the independent data monitoring committee (IDMC) on a regular basis for unblinded review.
| participants | Placebo | Pioglitazone | Rosiglitazone | VITAMIN D PLACEBO | VITAMIN D |
|---|---|---|---|---|---|
| Number of Participants With Need for Hospitalization for Any Reason | 31 | 16 | 24 | 19 | 32 |
CHF is a condition in which the heart is not able to pump adequate blood to meet the body's needs. Shortness of breath is defined as difficulty in breathing. Pneumonia is an infection of the lungs, caused by various microorganisms. Angina is defined as severe chest pain due to lack of adequate blood supply of the heart muscle because of obstruction/spasm of the heart's blood vessels. Data regarding the need for hospitalization due to any of these reasons were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.
| participants | Placebo | Pioglitazone | Rosiglitazone | VITAMIN D PLACEBO | VITAMIN D |
|---|---|---|---|---|---|
| CHF | 1 | 2 | 0 | 0 | 2 |
| Shortness of breath | 0 | 1 | 2 | 0 | 1 |
| Pneumonia | 0 | 1 | 0 | 0 | 0 |
| Angina | 3 | 1 | 1 | NA | NA |
The components of the composite microvascular outcome are retinopathy, decline in eGFR, vitrectomy, and renal replacement surgery. Retinopathy is defined as damage to the inner lining of the eye (retina). Decline in eGFR is defined as a \>=30% reduction in kidney function. Vitrectomy is a surgery to remove some or all of the fluid (vitreous humor) from the eye. Renal replacement therapy includes all the life-supporting treatments for renal failure. Data regarding the number of participants with changes in micro blood vessels (composite microvascular outcome) were collected at each visit.
| participants | Placebo | Pioglitazone | Rosiglitazone | VITAMIN D PLACEBO | VITAMIN D |
|---|---|---|---|---|---|
| Number of Participants With Composite Microvascular Outcome | 21 | 8 | 9 | 18 | 18 |
Retinopathy is defined as damage to the inner lining of the eye (retina). Decline in eGFR is defined as a \>=30% reduction in kidney function. Vitrectomy is a surgery to remove some or all of the fluid (vitreous humor) from the eye. Renal replacement therapy includes all the life-supporting treatments for renal failure. Data on the number of participants with all of these microvascular outcomes were collected at each visit. Data regarding the number of participants with these microvascular outcomes were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.
| participants | Placebo | Pioglitazone | Rosiglitazone | VITAMIN D PLACEBO | VITAMIN D |
|---|---|---|---|---|---|
| Retinopathy Requiring Laser Therapy | 1 | 0 | 0 | 0 | 0 |
| Decline in eGFR >=30% | 20 | 8 | 9 | 18 | 18 |
| Vitrectomy | 0 | 0 | 0 | 0 | 0 |
| Renal Replacement Therapy | 0 | 0 | 0 | 0 | 0 |
Severe hypoglycemia is defined as hypoglycemia requiring assistance from another person with either a documented plasma glucose \<=36 mg/deciliter (2.0 millimole per liter \[mmol/L\]) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration. Hypoglycemia data were obtained from outcomes reported by the site. Data regarding hypoglycemia were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.
| participants | Placebo | Pioglitazone | Rosiglitazone | VITAMIN D PLACEBO | VITAMIN D |
|---|---|---|---|---|---|
| Number of Participants With Severe Lower Than Normal Blood Glucose Level (Hypoglycemia) | 0 | 2 | 1 | 0 | 3 |
Clinical proteinuria is defined as a laboratory detection of urinary protein excretion \> 0.5 grams (g) per 24 hours; spot urine analysis for albumin:creatinine ratio \>=300 milligrams/g; timed urine collection for albumin excretion \>=200 µg/minute or \>=300 mg/24 hours. Clinical proteinuria data were obtained from outcomes reported by the site.
| participants | Placebo | Pioglitazone | Rosiglitazone | VITAMIN D PLACEBO | VITAMIN D |
|---|---|---|---|---|---|
| Number of Participants With Clinical Proteinuria | 1 | 0 | 0 | NA | NA |
Fracture is defined as a medical condition in which there is a break in the continuity of the bone. Fractures are defined as those breaks that are self reported plus confirmed by an X-ray. Data regarding all occurrences of any fracture were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.
| participants | Placebo | Pioglitazone | Rosiglitazone | VITAMIN D PLACEBO | VITAMIN D |
|---|---|---|---|---|---|
| Number of Participants With a Fracture | 2 | 2 | 3 | 3 | 3 |
Liver function tests are groups of clinical biochemistry laboratory blood assays designed to give information about the health of the liver. "Liver function test abnormal" and "hepatic enzyme increased" were obtained from adverse event data as reported by investigators based on the reference range of the reporting local laboratory methodology. The vitamin D arm was not analyzed for this outcome measure.
| participants | Placebo | Pioglitazone | Rosiglitazone | VITAMIN D PLACEBO | VITAMIN D |
|---|---|---|---|---|---|
| Number of Participants With Hepatic Enzyme Increased or Abnormal Liver Function Tests | 1 | 0 | 1 | NA | NA |
CD is equivalent to a difference of \>=1.5 units on the Digit Symbol Substitution Test (DSST) score. The DSST is a neuropsychological test sensitive to brain damage, a serious loss of cognitive ability, age, and depression. It consists of digit-symbol pairs, followed by a list of digits. Under each digit the participant was asked to write the corresponding symbol as quickly as possible. The number of correct symbols within the allowed time (90 or 120 seconds) was measured in units (one correct score equals one unit).
No measurements were reported for this outcome.
Erectile dysfunction (ED) is sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual performance. ED was assessed by using the International Index of Erectile Dysfunction (IIED) questionnaire. This standardized and validated 15-item self-evaluation scale provides pre- and post-treatment clinic evaluations of erectile and orgasmic function, sexual desire, satisfaction with sexual intercourse, and general satisfaction.
No measurements were reported for this outcome.
Quality of life (QoL) was assessed by using the Euro-QoL (EQ)-5D, a short questionnaire used for measuring health-related QoL. The preference weights are elicited by asking participants to place hypothetical health states on a visual analogue scale from "0" to "1", whereby a score of "1" represents the best health state imaginable and "0" represents a health state equivalent to being dead. Negative states are those worse than being dead.
No measurements were reported for this outcome.
CF was assessed with the 30-point (pt) MoCA test, involving a short-term memory recall task (T) (5 pts), a clock-drawing T (3 pts), a 3-dimensional cube copy (1 pt), a trail-making B T (1 pt), a phonemic fluency T (1 pt), a 2-item verbal abstraction T (2 pts), an attention T (1 pt), a serial subtraction T (3 pts), digits forward/ backward (1 pt each), a 3-item confrontation naming T (3 pts), repetition of 2 syntactically complex sentences (2 pts), and orientation to time/ place (6 pts). A score of 26 or above is normal.
No measurements were reported for this outcome.
Collected over 162 days for the TZD arm; 130 days for the vitamin D arm. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 7/541 (1.3%) | 36/541 (6.7%) |
| Pioglitazone | — | 5/392 (1.3%) | 35/392 (8.9%) |
| Rosiglitazone | — | 2/399 (0.5%) | 21/399 (5.3%) |
| Vitamin D Placebo | — | 2/614 (0.3%) | — |
| Vitamin D | — | 9/607 (1.5%) | — |
| Event | Placebo | Pioglitazone | Rosiglitazone | Vitamin D Placebo | Vitamin D |
|---|---|---|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 0/541 | 1/392 | 1/399 | 0/614 | 2/607 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/541 | 1/392 | 0/399 | 0/614 | 1/607 |
| Bronchial disorderRespiratory, thoracic and mediastinal disorders | 0/541 | 1/392 | 0/399 | 1/614 | 0/607 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/541 | 1/392 | 0/399 | 0/614 | 1/607 |
| Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/541 | 1/392 | 0/399 | 0/614 | 0/607 |
| Cholecystitis acuteHepatobiliary disorders | 0/541 | 0/392 | 1/399 | 0/614 | 0/607 |
| AngioplastySurgical and medical procedures | 1/541 | 0/392 | 0/399 | 0/614 | 1/607 |
| Aortic aneurysmVascular disorders | 1/541 | 0/392 | 0/399 | 0/614 | 0/607 |
| Aortic aneurysm repairSurgical and medical procedures | 1/541 | 0/392 | 0/399 | 1/614 | 0/607 |
| Chronic sinusitisInfections and infestations | 1/541 | 0/392 | 0/399 | 0/614 | 1/607 |
| Event | Placebo | Pioglitazone | Rosiglitazone | Vitamin D Placebo | Vitamin D |
|---|---|---|---|---|---|
| Edema peripheralGeneral disorders | 4/541 | 8/392 | 1/399 | — | — |
| EdemaGeneral disorders | 2/541 | 5/392 | 1/399 | — | — |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/541 | 3/392 | 4/399 | — | — |
| ConstipationGastrointestinal disorders | 0/541 | 3/392 | 1/399 | — | — |
| DiarrheaGastrointestinal disorders | 2/541 | 3/392 | 1/399 | — | — |
| MalaiseGeneral disorders | 1/541 | 3/392 | 0/399 | — | — |
| Cardiac failureCardiac disorders | 3/541 | 2/392 | 0/399 | — | — |
| Abdominal pain upperGastrointestinal disorders | 0/541 | 2/392 | 0/399 | — | — |
| DyspepsiaGastrointestinal disorders | 1/541 | 2/392 | 0/399 | — | — |
| NauseaGastrointestinal disorders | 2/541 | 2/392 | 0/399 | — | — |
| Age, Continuous(Years) | Placebo | Pioglitazone (PIO) | Rosiglitazone (RSG) | Total |
|---|---|---|---|---|
| Mean | 66.4 ± 6.8 | 66.3 ± 6.6 | 66.5 ± 6.4 | 66.4 ± 6.6 |
| Sex: Female, Male(Participants) | Placebo | Pioglitazone (PIO) | Rosiglitazone (RSG) | Total |
|---|---|---|---|---|
| Female | 220 | 167 | 161 | 548 |
| Male | 321 | 225 | 238 | 784 |
| Race/Ethnicity, Customized(participants) | Placebo | Pioglitazone (PIO) | Rosiglitazone (RSG) | Total |
|---|---|---|---|---|
| European/ Caucasian/ White | 330 | 241 | 255 | 826 |
| Unknown | 53 | 34 | 35 | 122 |
| South Asian | 63 | 46 | 48 | 157 |
| Black African | 45 | 35 | 26 | 106 |
| Native South American | 33 | 26 | 24 | 83 |
| Other Asian | 10 | 6 | 6 | 22 |
| Native North American | 1 | 2 | 4 | 7 |
| Japanese | 1 | 0 | 1 | 2 |
| Arab/ Persian | 1 | 1 | 0 | 2 |
| Native Hawaiian/ Australian or Other Asian Pacific | 1 | 1 | 0 | 2 |
| Malays | 1 | 0 | 0 | 1 |
| Sub-Saharan African | 1 | 0 | 0 | 1 |
| Missing | 1 | 0 | 0 | 1 |
Showing the first 100 of 331 sites across 25 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of May 2009, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pioglitazone · Rosiglitazone · Vitamin D